1.5201
price up icon1.87%   0.000100
 
loading
Precedente Chiudi:
$1.52
Aprire:
$1.5
Volume 24 ore:
38,314
Relative Volume:
0.79
Capitalizzazione di mercato:
$41.29M
Reddito:
$9.06M
Utile/perdita netta:
$-50.39M
Rapporto P/E:
-0.9871
EPS:
-1.54
Flusso di cassa netto:
$5.89M
1 W Prestazione:
-6.72%
1M Prestazione:
-10.00%
6M Prestazione:
-41.57%
1 anno Prestazione:
+3.93%
Intervallo 1D:
Value
$1.46
$1.58
Intervallo di 1 settimana:
Value
$1.50
$1.6673
Portata 52W:
Value
$1.35
$6.47

Lava Therapeutics Nv Stock (LVTX) Company Profile

Name
Nome
Lava Therapeutics Nv
Name
Telefono
-
Name
Indirizzo
-
Name
Dipendente
37
Name
Cinguettio
Name
Prossima data di guadagno
2024-11-14
Name
Ultimi documenti SEC
Name
LVTX's Discussions on Twitter

Confronta LVTX con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
LVTX 1.48 41.29M 9.06M -50.39M 5.89M -1.54
VRTX 448.70 115.43B 10.63B -479.80M -1.35B 13.33
REGN 746.20 82.04B 13.85B 4.65B 3.32B 35.06
ARGX 597.08 35.30B 1.86B -40.29M -1.28B -4.16
ALNY 246.44 32.04B 2.09B -332.26M 16.06M -4.14
BNTX 108.16 24.89B 3.30B -501.07M 1.03B 11.54

Lava Therapeutics Nv Stock (LVTX) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2022-10-25 Iniziato H.C. Wainwright Buy
2021-04-19 Iniziato JP Morgan Overweight
2021-04-19 Iniziato Jefferies Buy
2021-04-19 Iniziato SVB Leerink Outperform

Lava Therapeutics Nv Borsa (LVTX) Ultime notizie

pulisher
Sep 30, 2024

Lava Therapeutics' SWOT analysis: oncology biotech's stock potential amid trials - Investing.com UK

Sep 30, 2024
pulisher
Sep 21, 2024

Xinhua News | Portuguese scientists discover new approach to combat Alzheimer's disease - Xinhua

Sep 21, 2024
pulisher
Sep 16, 2024

After the Lykos debacle, what’s next for psychedelic therapies? - Pharmaceutical Technology

Sep 16, 2024
pulisher
Sep 16, 2024

Positive Pooled Data from Nuvation Bio’s TRUST-I and TRUST-II Studies Highlight Taletrectinib’s Best-in-Class Potential for Patients with Advanced ROS1-positive NSCLC, Supporting Planned New Drug Application Submission in the Fourth Quarter of 2024 - BioSpace

Sep 16, 2024
pulisher
Sep 05, 2024

LAVA Therapeutics Announces Appointment of Amy Garabedian as General Counsel and Corporate Secretary - Yahoo Finance UK

Sep 05, 2024
pulisher
Sep 04, 2024

LAVA Therapeutics to Participate in the H.C. Wainwright 26th Annual Global Investment Conference - Yahoo Finance UK

Sep 04, 2024
pulisher
Sep 04, 2024

LAVA Therapeutics to Participate in the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference - Yahoo Finance UK

Sep 04, 2024
pulisher
Sep 03, 2024

LVTXLAVA Therapeutics N.V. Ordinary Shares Latest Stock News & Market Updates - StockTitan

Sep 03, 2024
pulisher
Aug 22, 2024

LAVA Therapeutics (NASDAQ:LVTX) Given Market Outperform Rating at JMP Securities - Defense World

Aug 22, 2024
pulisher
Aug 21, 2024

LAVA Therapeutics (NASDAQ:LVTX) Issues Earnings Results - Defense World

Aug 21, 2024
pulisher
Aug 20, 2024

LAVA Therapeutics Faces Financial Hurdles - TipRanks

Aug 20, 2024
pulisher
Aug 20, 2024

LAVA Reports Second Quarter 2024 Financial Results and Business Update - GlobeNewswire

Aug 20, 2024
pulisher
Aug 16, 2024

LAVA Therapeutics NV expected to post a loss of 36 cents a shareEarnings Preview - XM

Aug 16, 2024
pulisher
Aug 13, 2024

LAVA Therapeutics (NASDAQ:LVTX) Stock Price Up 2.3% - Defense World

Aug 13, 2024
pulisher
Jul 22, 2024

All You Need to Know About LAVA Therapeutics (LVTX) Rating Upgrade to Strong Buy - Yahoo Finance Australia

Jul 22, 2024
pulisher
Jul 21, 2024

LAVA Therapeutics (NASDAQ:LVTX) Shares Down 0.7% - American Banking and Market News

Jul 21, 2024
pulisher
Jul 20, 2024

LAVA Therapeutics (NASDAQ:LVTX) Trading Down 0.7% - Defense World

Jul 20, 2024
pulisher
Jul 03, 2024

Investors in LAVA Therapeutics (NASDAQ:LVTX) from a year ago are still down 16%, even after 44% gain this past week - Yahoo Lifestyle Australia

Jul 03, 2024
pulisher
Jun 29, 2024

LAVA Therapeutics (NASDAQ:LVTX) Receives Buy Rating from HC Wainwright - Defense World

Jun 29, 2024
pulisher
Jun 28, 2024

Cathie Wood's ARK ETF focuses on PagerDuty, 10X Genomics stock By Investing.com - Investing.com

Jun 28, 2024
pulisher
Jun 28, 2024

Lava Therapeutics shares hold target with Buy rating By Investing.com - Investing.com India

Jun 28, 2024
pulisher
Jun 28, 2024

Macquarie starts Ensign Group stock coverage with outperform rating By Investing.com - Investing.com India

Jun 28, 2024
pulisher
Jun 28, 2024

Barclays sets Charles River Labs stock target with Equalweight rating By Investing.com - Investing.com India

Jun 28, 2024
pulisher
Jun 28, 2024

Citi reaffirms sell on Dr. Reddy's shares amid acquisition deal By Investing.com - Investing.com

Jun 28, 2024
pulisher
Jun 28, 2024

Jefferies sets buy rating on Syndax stock By Investing.com - Investing.com UK

Jun 28, 2024
pulisher
Jun 28, 2024

UBS starts Hydro One stock coverage with neutral rating By Investing.com - Investing.com UK

Jun 28, 2024
pulisher
Jun 28, 2024

Lava Therapeutics shares hold target with Buy rating - Investing.com India

Jun 28, 2024
pulisher
Jun 27, 2024

JPMorgan starts PagerDuty stock with neutral rating amid 'competitive landscape' By Investing.com - Investing.com Australia

Jun 27, 2024
pulisher
Jun 27, 2024

Cava group director Bosserman sells over $2.7 million in company stock By Investing.com - Investing.com Canada

Jun 27, 2024
pulisher
Jun 25, 2024

Goldman Sachs sets target on Paramount shares, initiates with sell By Investing.com - Investing.com

Jun 25, 2024
pulisher
Jun 21, 2024

Transocean adjusts share capital and treasury shares By Investing.com - Investing.com

Jun 21, 2024
pulisher
Jun 20, 2024

LAVA Therapeutics Shareholders Approve Key ResolutionsTipRanks.com - TipRanks

Jun 20, 2024
pulisher
Jun 19, 2024

Metric Analysis: LAVA Therapeutics NV (LVTX)'s Key Ratios in the Limelight – DWinneX - The Dwinnex

Jun 19, 2024
pulisher
Jun 17, 2024

Kayne Anderson BDC stock gets Market Perform from KBW, notes stable industry focus By Investing.com - Investing.com

Jun 17, 2024
pulisher
Jun 14, 2024

Biopharma Layoff Tracker 2024: Barinthus, Agilent, BMS and More Cut Staff - BioSpace

Jun 14, 2024
pulisher
Jun 14, 2024

Kinsale Capital's president and COO sells shares worth over $579,000 By Investing.com - Investing.com South Africa

Jun 14, 2024
pulisher
Jun 10, 2024

LAVA Announces Annual Meeting of Shareholders - GlobeNewswire

Jun 10, 2024
pulisher
Jun 07, 2024

BioCardia secures patent for cardiac delivery catheter By Investing.com - Investing.com India

Jun 07, 2024
pulisher
Jun 06, 2024

Karyopharm CEO sells shares worth $3,556 By Investing.com - Investing.com

Jun 06, 2024

Lava Therapeutics Nv Azioni (LVTX) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$18.98
price up icon 1.80%
$70.68
price down icon 0.42%
$38.38
price up icon 3.49%
$369.83
price up icon 1.48%
$196.58
price up icon 0.88%
$102.64
price up icon 0.27%
Capitalizzazione:     |  Volume (24 ore):